Tejas Savant, an analyst from Morgan Stanley, maintained the Hold rating on Adaptive Biotechnologies (ADPT – Research Report). The associated price target remains the same with $7.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Tejas Savant’s rating is based on the company’s stable performance and strategic guidance. Adaptive Biotechnologies reported a slight revenue increase in the fourth quarter of 2024, primarily driven by its clonoSEQ clinical testing and pharmaceutical partnerships. Despite challenges in the Immune Medicine segment, the company managed to exceed expectations in the MRD revenue, which was bolstered by retrospective coverage benefits.
Looking ahead, the company’s guidance for 2025 suggests steady revenue expectations with a focus on the second half of the year due to anticipated ASP growth and the expansion of electronic medical record (EMR) rollouts. The firm remains cautious about pharmaceutical partnerships, yet aims for EBITDA and cash flow break-even points in late 2025 and early 2026, respectively. The ongoing progress in reducing costs and improving execution in the clonoSEQ program is crucial for potential stock upside, which supports the Hold rating.
Savant covers the Healthcare sector, focusing on stocks such as Stevanato Group, Charles River Labs, and Hologic. According to TipRanks, Savant has an average return of -2.1% and a 40.99% success rate on recommended stocks.
In another report released on January 28, Goldman Sachs also maintained a Hold rating on the stock with a $7.50 price target.